Actively Recruiting
Exploring Fluzoparib Maintenance for Advanced Triple-Negative Breast Cancer After Platinum Therapy in Women With or Without BRCA Mutations
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2026-08-21
72
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the use of fluzoparib, a poly ADP-ribose polymerase PARP inhibitor, as maintenance therapy in women with advanced triple-negative breast cancer TNBC. This study focuses on patients who have benefited from prior platinum-based treatments, including those with BRCA12 mutations or wild-type BRCA. The research aims to evaluate the effectiveness and safety of fluzoparib in this specific group, addressing limited data in Chinese patients and those without BRCA mutations. Participants will receive fluzoparib orally at a dose of 150 mg twice daily in 28-day cycles. Treatment continues until the disease progresses, unacceptable side effects occur, consent is withdrawn, or death. Dose adjustments are permitted for certain toxicities. No other anticancer treatments are allowed during the study. Tumor response will be assessed by CT or MRI scans every six weeks, and optional biomarker samples may be collected for further analysis. During the study, participants will be monitored regularly for disease progression, side effects, and overall health. Key outcomes include progression-free survival measured from the first dose of fluzoparib until disease progression or death, assessed every six weeks up to 12 months. Additional measurements include overall survival, duration of response, disease control rate, and safety assessments, with follow-up lasting up to approximately 36 months.
CONDITIONS
Brief Title
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
Research Team
W
Weipeng Zhao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here